Cat# : THP-0007
|THP-0007||Aldesleukin; Recombinant Modified Human interleukin-2||April 02, 2023||100ug||$798||
|Add to Cart Online Order Request a Bulk Order|
|Product Name:||Aldesleukin; Recombinant Modified Human interleukin-2|
|Description:||The product, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) The product is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.|
|Molecular Weight:||15314.8 Da|
|Purity:||>99% by SDS-Page and HPLC analysis|
|Endotoxin Level:||<0.001 EU per 1 μg of the peptide by the LAL method|
|Biological Activity:||22000000 unit / vial|
|Storage:||Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.|
|Applications:||For treatment of adults with metastatic renal cell carcinoma.|
|Examples of Clinical Use:||Metastatic renal cell carcinoma|
|Pharmacodynamics:||Used to treat renal cell carcinoma, the product induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.|
|Mechanism of action:||Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.|
|Affected organisms:||Humans and other mammals|
|Targets:||Target 1. Interleukin-2 receptor subunit beta; Target 2. Interleukin-2 receptor subunit alpha; Target 3. Cytokine receptor common subunit gamma; Enzyme 1. Prostaglandin G/H synthase 2; Enzyme 2. Cytosolic phospholipase A2; Enzyme 3. Cytochrome P450 3A4; Enzyme 4. Xanthine dehydrogenase/oxidase; Enzyme 5. Cytochrome P450 2E1|
|THP-0004||Talimogene laherparepvec; T-Vec||Inquiry|
|THP-0009||Keyhole limpet hemocyanin(KLH)||1mg||$2,998||Add to CartOrder|
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.